Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;46(2):300-309.
doi: 10.1002/jpen.2272. Epub 2021 Oct 21.

Teduglutide in short bowel syndrome patients: A way back to normal life?

Felix Harpain  1 , Lukas Schlager  1 , Elisabeth Hütterer  2 , Christopher Dawoud  1 , Sabine Kirchnawy  1 , Judith Stift  3 , Pavla Krotka  4 , Anton Stift  1
Affiliations

Teduglutide in short bowel syndrome patients: A way back to normal life?

Felix Harpain et al. JPEN J Parenter Enteral Nutr. 2022 Feb.

Abstract

Background: The glucagon-like peptide 2 analogue teduglutide is an effective drug for the treatment of short bowel syndrome patients with intestinal failure (SBS-IF). This intestinotrophic peptide improves intestinal capacity for fluid and nutrient absorption through induction of mucosal growth and reduction of gastrointestinal motility. Clinical trials demonstrated the efficacy of teduglutide in reducing the need for parenteral support (PS). This study describes an SBS-IF patient population receiving teduglutide therapy in a specialized medical care setting.

Method: A retrospective analysis was performed using data of patients experiencing nonmalignant SBS-IF. They were treated with teduglutide in a multidisciplinary SBS-IF program at a single university medical center between June 2016 and June 2020.

Results: Thirteen patients under teduglutide treatment were included in the final analysis. Mean small bowel length was 82 ± 31 cm, with 77% of patients having their colon in continuity. Over a median follow-up of 107 weeks, all patients (13 of 13, 100%) responded to the therapy with a clinically significant reduction of PS volume. Mean PS reduction increased with therapy duration and ranged from -82.5% at week 24 (n = 13) to -100% in patients (n = 5) who were treated for 144 weeks. Enteral autonomy was achieved in 12 of 13 (92%) patients. Teduglutide therapy improved stool frequency and consistency, changed dietary habits, and reduced disease-associated sleep disruptions.

Conclusion: Integrating SBS-IF patients treated with teduglutide in a proactive and tight-meshed patient care program significantly improves the clinical outcome, leading to an increased proportion of patients reaching enteral autonomy.

Keywords: enteral autonomy; glucagon-like peptide 2; intestinal failure; short bowel syndrome; teduglutide.

PubMed Disclaimer

Conflict of interest statement

Felix Harpain reports a grant and lecture fee from Takeda, outside the submitted work. Elisabeth Hütterer and Anton Stift report lecture fees from Takeda, outside the submitted work. Lukas Schlager, Christopher Dawoud, Sabine Kirchnawy, Judith Stift, and Pavla Krotka have indicated they have no conflict of interests to disclose.

Figures

Figure 1
Figure 1
Effect of teduglutid treatment on PS requirements. (A) Meane (SE) reduction of PS volume and increase of mean (SE) BMI from baseline. (B) Distribution of responders over time. BMI, body mass index; PS, parenteral support
Figure 2
Figure 2
Summary of changes in (A) mean (SE) PS volume, (B) mean (SE) oral fluid volume, (C) mean (SE) urine volume, and (D) mean (SE) fluid composite effect from baseline. PS, parenteral support
Figure 3
Figure 3
Effect of teduglutide treatment on stool characteristics. (A) Mean (SE) reduction of stool frequency from baseline. (B) Change of stool consistency from baseline
Figure 4
Figure 4
Effect of teduglutide treatment on dietary habits. (A) Mean (SE) increase of meal frequency from baseline. (B) Change of meal size from baseline
Figure 5
Figure 5
Mean (SE) sleep disruptions per night
See this image and copyright information in PMC

References

    1. Jeppesen PB. Spectrum of short bowel syndrome in adults: intestinal insufficiency to intestinal failure. JPEN J Parenter Enteral Nutr. 2014;38(1 Suppl):8S‐13S. - PubMed
    1. Jeppesen PB. Pharmacologic options for intestinal rehabilitation in patients with short bowel syndrome. JPEN J Parenter Enteral Nutr. 2014;38(1 Suppl):45S‐52S. - PubMed
    1. Jeppesen PB. Teduglutide, a novel glucagon‐like peptide 2 analog, in the treatment of patients with short bowel syndrome. Therap Adv Gastroenterol. 2012;5(3):159‐171. - PMC - PubMed
    1. Jeppesen PB. New approaches to the treatments of short bowel syndrome‐associated intestinal failure. Curr Opin Gastroenterol. 2014;30(2):182‐188. - PubMed
    1. Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon‐like peptide 2. Proc Natl Acad Sci U S A. 1996;93(15):7911‐7916. - PMC - PubMed

MeSH terms